Polynucleotide encoding an anti-FGF19 antibody

Details Polynucleotide encoding an anti-FGF19 antibody Polynucleotide encoding an anti-FGF19 antibody

2010-01-22

2010-12-07

Mertz, Prema (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S325000, C435S252300, C435S320100, C536S023530

Reexamination Certificate

active

07846691

ABSTRACT:
The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.

REFERENCES:
patent: 6632927 (2003-10-01), Adair et al.
patent: 7678373 (2010-03-01), Desnoyers et al.
patent: 2002/0012961 (2002-01-01), Botstein et al.
patent: 2002/0042367 (2002-04-01), Stewart et al.
patent: 2002/0155543 (2002-10-01), Adams et al.
patent: 2004/0126852 (2004-07-01), Stewart et al.
patent: 2004/0146908 (2004-07-01), Adams et al.
patent: 2005/0026243 (2005-02-01), Stewart et al.
patent: 2005/0026832 (2005-02-01), Adams et al.
patent: 2005/0196842 (2005-09-01), Botstein et al.
patent: 2007/0042395 (2007-02-01), Botstein et al.
patent: 2007/0077626 (2007-04-01), Botstein et al.
patent: WO-99/27100 (1999-06-01), None
patent: WO-01/18210 (2001-03-01), None
patent: WO-02/46467 (2002-06-01), None
patent: WO-03/025138 (2003-03-01), None
patent: WO-03/065006 (2003-08-01), None
patent: WO-03/103725 (2003-12-01), None
patent: WO-2007/136893 (2007-11-01), None
Abbass et al. (Apr. 1997). “Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas,”J. Clin. Endocrinol. Metab. 82(4):1160-1166.
Amit, A.G. et al. (Aug. 15, 1986). “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution,”Science233(4765):747-753.
Desnoyers, L.R. et al. (Jan. 3, 2008, e-pub. Jun. 25, 2007). “Targeting FGF19 Inhibits Tumor Growth in Colon Cancer Xenograft and FGF19 Transgenic Hepatocellular Carcinoma Models,”Oncogene27(1):85-97.
Eswarakumar et al. (Apr. 2005). “Cellular Signaling by Fibroblast Growth Factor Receptors,”Cytokine Growth Factor Rev. 16(2):139-149.
Fu et al. (Jun. 2004). “Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietry and Leptin-Deficient Diabetes,”Endocrinology145(6):2594-2603.
Gutierrez et al. (Feb. 2006). “Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels via FXR-Mediated Signaling of FGFR4,”Arterioscler. Thromb. Vasc. Biol. 26(2):301-306.
Harmer et al. (Jan. 27, 2004). “The Crystal Structure of Fibroblast Growth Factor (FGF) 19 Reveals Novel Features of the FGF Family and Offers a Structural Basis for its Unusual Receptor Affinity,”Biochemistry43(3):629-640.
Holt et al. (Jul. 1, 2003).“Definition of a Novel Growth Factor-Dependent Signal Cascade for the Suppression of Bile Acid Biosynthesis,”Genes Dev. 17(13):1581-1591.
Hotzel, K.H. et al. (Sep. 2007). “Targeting FGF19 as a Therapeutic for Hepatocellular Carcinoma,” Posterpresented at 14thEuropean Cancer Conference(ECCO 14), Barcelona, Spain, Sep. 23-27, 2007,EJC Supplements5(4):65, Abstract No. 328.
International Search Report mailed Mar. 28, 2008, for PCT Application No. PCT/US2007/061936, filed Feb. 9, 2007, six pages.
Jaakkola et al. (May 28, 1993). “Amplification of fgfr4 Gene in Human Breast and Gynecological Cancers,”Int. J. Cancer54(3):378-382.
Jeffers et al. (Aug. 2002). “Fibroblast Growth Factors in Cancer: Therapeutic Possibilities,”Expert Opin. Ther. Targets6(4):469-482.
Kan et al. (May 28, 1999). “Specificity for Fibroblast Growth Factors Determined by Heparan Sulfate in an Binary Complex with the Receptor Kinase,”J. Biol. Chem. 274(22):15947-15952.
Kiuri-Kuhlefelt et al. (Apr. 2000). “FGF4 and INT2 Oncogenes are Amplified and Expressed in Kaposi's Sarcoma,”Mod. Pathol. 13(4):433-437.
Morimoto et al. (Nov. 15, 2003). “Single Nucleotide Polymorphism in Fibroblast Growth Factor Receptor 4 at Codon 388 is Associated with Prognosis in High-Grade Soft Tissue Sarcoma,”Cancer98(10):2245-2250.
Nicholes, K. et al. (Jun. 2002). “Animal Model: A Mouse Model of Hepatocellular Carcinoma, Ectopic Expression of Fibroblast Growth Factor 19 in Skeletal Muscle of Transgenic Mice,”American Journal of Pathology160(6):2295-2307.
Nishimura et al. (Jan. 18, 1999). “Structure and Expression of a Novel Human FGF, FGF-19, Expressed in the Fetal Brain,”Biochim. Biophys. Acta1444(1):148-151.
Ozawa et al. (Sep. 5, 1966). “Expression of the Fibroblast Growth Factor Family and Their Receptor Family Genes During Mouse Brain Development,”Brain Res. Mol. Brain Res. 41(1-2):279-288.
Panka, D.J. et al. (May 1, 1988). “Variable Region Framework Differences Result in Decreased of Increased Affinity of Variant Anti-Digoxin Antibodies,”Proc. Natl. Acad. Sci. USA85(9):3080-3084.
Partanen et al. (Jun. 1991). “FGFR-4, a Novel Acidic Fibroblast Growth Factor Receptor with a Distinct Expression Pattern,”EMBO Journal10(6):1347-1354.
Penault-Llorca et al. (Apr. 10, 1995). “Expression of FGF and FGF Receptor Genes in Human Breat Cancer,”Int. J. Cancer61(2):170-176.
Qian et al. (Apr. 2004). “Cytoplasmic Expression of Fibroblast Growth Factor Receptor-4 in Human Pituitary Adenomas: Relation to Tumor Type, Size, Proliferation, and Invasiveness,”J. Clin. Endocrinol. Metab. 89(4):1904-1911.
Ron et al. (Mar. 15, 1993). “Fibroblast Growth Factor Receptor 4 is a High Affinity Receptor for Both Acidic and Basic Fibroblast Growth Factor but not for Keratinocyte Growth Factor,”Journal of Biological Chemistry268(8):5388-5394.
Rudikoff, S. et al. (Mar. 15, 1982). “Single Amino Acid Substitution Altering Antigen-Binding Specificity,”Proc. Natl. Acad. Sci. USA79(6):1979-1983.
Schlessinger (Nov. 26, 2004). “Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors,”Science306(5701):1506-1507.
Spinola et al. (Oct. 10, 2005). “Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients,”J. Clin. Oncol. 23(29):7307-7311.
Stark et al. (Oct. 1991). “FGFR-4, a New Member of the Fibroblast Growth Factor Receptor Family, Expressed in the Definitive Endoderm and Skeletal Muscle Lineages of the Mouse,”Development113(2):641-651.
Streit et al. (Aug. 20, 2004). “Involvement of the FGFR4 Arg388 Allele in Head and Neck Squamous Cell Carcinoma,”Int. J. Cancer111(2):213-217.
Tomlinson et al. (May 2002). “Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity,”Endocrinology143(5):1741-1747.
Wang et al. (Jan. 1994). “Fibroblast Growth Factor Receptors Have Different Signaling and Mitogenic Potentials,”Molecular&Cellular Biology14(1):181-188.
Xie et al. (Oct. 1999). “FGF-19, a Novel Fibroblast Growth Factor with Unique Specificity for FGFR4,”Cytokine11(10):729-735.
Yamada et al. (Apr. 2002). “Fibroblast Growth Factor Receptor (FGFR) 4 Correlated with the Malignancy of Human Astrocytomas,”Neurol Res. 24(3):244-248.
Yu et al. (May 19, 2000). “Elevated Cholesterol Metabolism and Bile Acid Synthesis in Mice Lacking Membrane Tyrosine Kinase Receptor FGFR4,”J. Biol. Chem. 275(20):15482-15489.

Affiliated with

Also associated with

Rating

Polynucleotide encoding an anti-FGF19 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polynucleotide encoding an anti-FGF19 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide encoding an anti-FGF19 antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4199478